ArticleFrontiers in oncology2026
Muscle size and muscle fat infiltration in patients with newly diagnosed prostate cancer: a case-control study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Cancer is a recognized risk factor for sarcopenia. While some studies suggest that androgen deprivation therapy (ADT) may contribute to muscle loss in patients with prostate cancer (PCa), it remains unclear whether alterations in muscle composition are already present at the initial diagnosis, before any treatment begins. This study aimed to evaluate computed tomography (CT)-based muscle size and muscle fat infiltration in patients with newly diagnosed prostate cancer. Methods: A total of 143 patients with newly diagnosed PCa (January 2023-June 2024) were enrolled and matched 1:2 with 286 controls. CT attenuation and cross-sectional area of the erector spinae (ES) and full-layer muscle at the T12 level were measured. The muscle-to-spleen attenuation ratio (M/S) was calculated. Muscle fat infiltration was assessed based on muscle CT attenuation. Multivariable logistic regression analyses were performed to examine the association between PCa and the risk of low muscle CT attenuation or low muscle area. Results: In PCa patients, muscle CT attenuation, M/S ratio, ES area, and full-layer muscle area decreased with advancing age. Overall, muscle CT attenuation and M/S ratio were significantly lower in the PCa group than in controls. Both ES area and full-layer muscle area were also significantly reduced in PCa patients younger than 70years. A similar difference in ES area was observed in the 70-80-year age group. After full adjustment, PCa was significantly associated with an increased risk of low ES CT attenuation (OR=2.59, 95%CI: 1.25-5.39), low full-layer muscle CT attenuation (OR=7.14, 95%CI: 3.30-15.45), low full-layer muscle M/S ratio (OR=4.29, 95%CI: 2.01-8.87), and low ES area (OR=2.94, 95%CI: 1.33-6.53). Similar associations were observed in the non-diabetic subgroup. Conclusion: Newly diagnosed prostate cancer is associated with an increased risk of CT-based skeletal muscle fat infiltration and reduced muscle area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.